SUMMARY. The LKB 'DelfiaTM, immunofluorometric assay for serum TSH has been evaluated. The assay is simple and rapid to perform and is capable of processing in excess of 100 specimens within a working day. The sensitivity of the assay is 0·05 mUlL, with a working range extending beyond 324 mUlL. The change in signal at each point over the standard curve approaches l000-fold, significantly greater than that of a typical immunoradiometric assay.
Mean figures for intra-assay and inter-assay precision were 4·7% and 8·6% CV, respectively. Mean recovery of added TSH was 98·3%, and samples containing high levels of endogenous TSH diluted parallel to the standard curve. The method showed good correlation with an immunoradiometric assay for TSH. The reference ranges for clinically defined groups of subjects were euthyroid 0·47-3'84 mUlL (n=83); primary hypothyroidism 15 -> 324 mUlL (n=28); thyrotoxicosis
<0·05 mUlL (n=46).
It is concluded that the 'Delfia' assay offers the clinical biochemistry laboratory an attractive and reliable alternative to a sensitive immunoradiometric assay for serum TSH.
The recent introduction of sensitive immunometric assays for serum thyroid stimulating hormone (TSH) has contributed to improved clinical discrimination of patients with thyroid disease. I, 2 In order to achieve good precision from an immunoradiometric assay (IRMA) at low levels of TSH, it is necessary to count the radioactive signal from each sample for a relatively long time-period, and this has led to a search for alternative non-isotopic labels. 3.4 The LKB-Wallac dissociationenhanced lanthanide fluoroimmunoassay ('DelfiaTM,) is the first such non-isotopic assay to be available in commercial form, and we have evaluated its performance' and compared its clinical discrimination with that of a commonly used IRMA.
Materials and methods
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606 fluorometric assay (IFMA) which employs two monoclonal antibodies directed against different antigenic determinants on the~subunit of the TSH molecule. One monoclonal antibody is physically adsorbed to a microtitre strip-well in which the assay is performed. The other monoclonal antibody is labelled with a europium (Eu) chelate. Europium is the label of choice because it has a wide excitation wavelength band, a narrow emission wavelength band, a large Stokes shift and a long fluorescence decay time relative to other conventional tluorophores." Before measuring fluorescence, an enhancement solution is added to promote the dissociation of Eu3+ cations from the labelled antibody into solution where they form highly fluorescent chelates with components of the enhancement solution. Nonspecific background fluorescence is minimised by counting in the time-resolved mode, whereby a delay of 400 us elapses after excitation prior to measurement of the fluorescence. During this delay, virtually all short-lived fluorescence disappears.v 6 The whole excitation/counting cycle is completed in 1 s. A variety of different immunoassay methods em-A typical standard curve of fluorescence (cps) against concentration (mUlL) is depicted in Fig. 2 . Linearity extends from the 0·25 mUlL standard to at least the 324 mUlL standard. The change in signal over the range of this standard curve is 867-fold, from 1·5xHP cps at zero to 1·3 X 10 6 cps at 324 mUlL. The sensitivity of the assay, calculated as three times the standard deviation of 30 zero-standard measurements was 0·05 mUlL. In addition, the sensitivity of the assay, calculated as three times the standard from clinically defined patients with untreated thyroid disease were obtained from the Thyroid Clinics at Glasgow Royal Infirmary and the Western General Hospital in Edinburgh. Thirdly, selected samples were taken from the busy routine work-load of the authors' department. For comparative purposes, Delfia TSH results were compared with those obtained on the same sample with the Boots-Celltech IRMA, used according to the manufacturer's recommended method.
The Delfia TSH assay kits were used according to the recommendations of the manufacturer. A flow chart for the method appears in Fig. 1 . The counting time employed was one second per well. Intra-and inter-assay precision was assessed over the range 1·2-82 mUlL. The recovery of added TSH was determined at three different Ievels, and assay parallelism was assessed by serial dilution in assay buffer of serum from hypothyroid patients. A formal cross-reactivity study was performed with human chorionic gonadotrophin (hCG). ploying this principle have now been described.i!' Each Delfia kit contained a 96-well microtitre plate consisting of eight individual 12-well strips; a bottle containing Eu-labelled monoclonal anti-TSH; six vials containing TSH standards to cover the range 0-324 mUlL; 500 mL of assay buffer (Tris/NaCI containing bovine serum albumin, bovine globulin, Tween 40, sodium azide and diethylenetriamine-penta acetic acid); 20 mL of wash concentrate (saline containing Tween 20 and sodium azide) and 50 mL of enhancement solution (containing potassium hydrogen phthalate, acetic acid, tri-N-octyl phosphine oxide, 2-napthoyl trifluoroacetone and Triton X-100). Each kit was capable of accommodating six standards, three quality controls and 39 unknown samples, estimated in duplicate. Kits were stored at 4°C prior to use.
The instrumentation employed for the measurement of the time-resolved fluorescence was the LKB-Wallac 'Arcus' 1230 fluorometer" with accompanying disc drive, software and matrix printer. A Dynatech microtitre plate shaker and a Skatron microtitre strip wash device were also used.
Serum deviation of the zero-standard from a standard deviation precision profile, was 0·03 mUlL. These two methods of calculating sensitivity are approximately comparable.
An intra-assay precision profile from 15 different assays including more than 700 data points is shown in Fig. 3 . The assay exhibits a mean intra-assay coefficient of variation (CV) below 10% from 0·2-324 mUlL TSH, and gives a maximum precision of 3% at 15 mUlL TSH. Intra-assay precision over the range 1·2-82 mUlL TSH is presented in Table 1 . A mean intra-assay CV of 4·7% was obtained.
The inter-assay CV was determined at three different levels from the results of 29 different assays. The results displayed in Table 2 reveal a mean CV of 8·6%. Table 3 shows that the Delfia TSH assay quantitatively recovers added TSH (Second International Reference Preparation MRC 80/558) over the range 0'88-17·6 mUlL. Fig. 4 demonstrates that samples containing high levels of serum TSH dilute in a linear fashion, indicating parallelism with the standard curve. These data agree well with % CYs from the precision profile shown in Fig. 3 . nancy was 1·03 mUlL, not significantly different from that found in non-pregnant, euthyroid subjects.
The correlation between 85 serum TSH results as determined by Delfia and the BootsCelltech IRMA is recorded in Fig. 5 . Linear regression analysis gives a correlation coefficient of 0·960, identifying good agreement between methods. The logarithmic scale, used to cope with the wide range of values covered, is somewhat misleading, for it appears as though the points lie close to the line of complete identity. In fact, the gradient for the correlation (0'72) indicates that the IRMA yields consistently higher results than Delfia. Statistical analysis (Wilcoxon sign rank test) of this paired data proves that the Boots-Celltech results are significantly higher than Delfia results (P<O·OOI). Figure 6 shows the discrimination obtained with the Delfia TSH assay between clinically defined groups of patients. None of the patients with primary hypothyroidism or thyrotoxicosis had received treatment at the time of study. The euthyroid reference range (n=83) was 0·47-3·84 mUlL (mean 1·52 mUlL; median 1-44 mUlL), which was clearly separated from the primary hypothyroid reference range of 15-> 324 mUlL (n=28). All the 46 patients with thyrotoxicosis had serum TSH levels :0::0·05 mUlL. The Arcus 1230 time-resolved fluorometer has proved to be a reliable and robust instrument throughout the 6-month evaluation period. It is simple to use and is capable of counting, calculating and printing results from a 96-well assay in less than 10 min. The software package is adequate for most routine clinical purposes. Assay time, capital equipment costs and costs per test are comparable with other currently available commercial IRMA's, such as the Boots-Celltech system.
The Delfia TSH assay has proved to be simple to perform and capable of processing in excess of 100 unknown serum samples within a single working day. The assay performs with intra-and inter-assay precision that is better than the vast majority of TSH assays currently available. The assay recovers added TSH quantitatively at a number of different levels, indicating satisfactory standardisation. Elevated serum TSH dilutes parallel to the standard curve, indicating the absence of a matrix effect and the similar behaviour of standard and physiological TSH.
The cross-reactivity with human chorionic gonadotrophin was minimal. However, an apparent serum TSH of 0·3 mUlL due to hCG interference could lead to problems of misclassification of the pregnant thyrotoxic patient. In this study we were unable to distinguish between a true cross-reactivity and a possible low level contamination of the hCG preparation with TSH-like material. The fact that a small number of euthyroid pregnant subjects had mean TSH levels no higher than the mean of the non-pregnant euthyroid range lends support to the latter option. However, the real answer to this question will have to await a study of Delfia TSH levels in pregnant thyrotoxic patients.
The correlation between Delfia TSH and Boots-Celltech IRMA TSH over a wide range of concentrations was good, indicating very close agreement in the ranking of results. The intercept from the correlation was higher than expected but did not differ significantly from zero, and was probably brought about by a tendency for the results of the two methods to diverge more at levels > 100 mUlL than at levels <100 mUlL. The gradient from the correlation was, however, significantly different from unity, with the Boots-Celltech assay giving results 28% higher than the Delfia assay, a fact which accords with the higher reference range reported for the IRMA. As both immunometric assays recover added TSH quantitatively and appear to be free of matrix effects, it is not possible to say which of the assays, if either, is yielding the 'correct' results. The most likely explanation of the systematic difference between the assays lies in a potency difference, which may be related to the relative specificities of the assays for endogenous and standard TSH, as dictated by the particular monoclonal antibodies employed. A systematic difference of this nature has implications for the external quality assessment of TSH assays and for the interpretation of clinical results between different immunometric assays for TSH.
The discrimination between defined clinical groups of patients achieved with the Delfia TSH assay was excellent and equivalent to the best of the sensitive IRMA systems. I, 2 It remains to be established how this discrimination will be affected in routine clinical practice, particularly when sera from acutely and chronically ill patients and patients being treated for thyroid disease are examined. It is likely, however, that the Delfia TSH assay will serve as well as the best of the recently available sensitive TSH assays, as a first line test of thyroid function, together with some measurement of thyroxine status. I In conclusion, we have demonstrated that the Delfia TSH assay performs well in the laboratory and is capable of excellent clinical discrimination. The signal obtained across the range of the curve is some SOO-fold greater than that given by a typical IRMA and, as such, suggests that Delfia should offer advantages of sensitivity and precision over assays based on radioactive labels.
